Regenerative Therapies Market is Expected to Reach $45,940.7 Million by the End of 2027 | BioStem Life Sciences, Akron Biotechnology, LLC, Organovo Holdings Inc.

A New Market Study on Regenerative Therapies Market 2022-2028 with 100+ Market Data Tables, Pie Chart and Graphs and Figures spread over pages and easy to understand detailed analysis. Currently, the market is expanding its presence. The research report presents a comprehensive assessment of the market and contains future trend, current growth factors, careful opinions, facts and industry-validated market data. The report incorporates broad evaluation of different methods such as combinations and acquisitions, advancements, investigations, and improvements adopted by observable market pioneers to stay ahead in the overall market.

Get a PDF brochure with the latest information @ https://www.coherentmarketinsights.com/insight/request-pdf/3712

Regenerative therapies use the patient’s own cells to repair damaged tissue. Generally, these stem cells come from the patient’s bone marrow or fatty tissue. The term “regenerative” is an umbrella term for various procedures that use substances from the body to treat various conditions. A doctor may administer one or more of these therapies depending on the nature of the disease. The recovery period can last several weeks or even months, so the benefits can be immediate.

The Global regenerative therapies market is estimated to be worth US$10,421.5 million in 2019 and is expected to reach US$45,940.7 million by the end of 2027.

Global Regenerative Therapies Market: Drivers

The growing popularity of stem cell technique is expected to propel the growth of the global regenerative therapies market over the forecast period. For example, according to the study “The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions,” published in the journal Perspectives in Biology and Medicine, in 2018 the number of new stem cell companies with websites doubled. on average each year between 2009 and 2014, in the United States

Get a sample report with the latest Covid19 impact analysis @ https://www.coherentmarketinsights.com/insight/request-sample/3712

Global Regenerative Therapies Market: Opportunities

The high prevalence of neurological disorders is expected to provide lucrative growth opportunities for market players. For example, according to the study “Prevalence of Parkinson’s disease (PD) across North America”, published in July 2018 in the journal Nature, the number of people with Parkinson’s disease is expected to reach 930,000 in 2020 and 1,238,000 in 2030.

Global Regenerative Therapies Market: Constraints

Factors such as lack of financial support from small businesses are expected to limit the growth of the global regenerative therapies market. A common factor in the regenerative therapy industry is the unavailability of suitable financing options for small organizations. This is one of the main obstacles to R&D in the field of regenerative therapies. Fairly seen in resource-poor settings, many promising targets were dropped midway through the clinical trial phase due to a lack of financial support resulting from insufficient data on proven efficacy. Additionally, the emergence of start-ups that research and produce regenerative therapies has been hampered by the lack of lucrative co-marketing collaborations from medical device companies (particularly in orthopedics – the largest segment in terms of revenue generation) and licensing and out-licensing agreements.

Key points to remember:

Allograft held a dominant position in the global regenerative therapies market in 2019, accounting for 57.7% share by value, followed by xenograft and alloplast, respectively. Allograft is a regenerative biological material that is transplanted from one person to another, that is, from a donor to a recipient. The growing applications of this product are expected to support the growth of the segment.

The orthopedic segment held a dominant position in the global regenerative therapies market in 2019, accounting for 37.2% share by value, followed by soft tissue repair and cardiovascular system respectively. Increase in research activities and rapid development of innovative products by key players is expected to drive the growth of the segment. For example, in 2015, NuVasive Inc., a US-based company, launched its innovative new biotechnology, AttraX Putty, which is a synthetic bone graft, indicated in posterolateral spinal surgery as an autograft expander.

The hospital segment held a dominant position in the global regenerative therapies market in 2019, accounting for 84.3% share by value, followed by outpatient surgical centers and teaching institutes, respectively.

Market trends

The major players are focusing on the development of new biotherapeutic product platforms to expand their product portfolio. For example, in March 2020, Pluristem Therapeutics Inc., a regenerative medicine company, announced that it had dosed three patients at two different hospitals in Israel under a compassionate use program for the treatment of COVID- 19.

Major players are also focusing on expanding their capabilities. For example, in March 2020, BioStem Life Sciences, a subsidiary of BioStem Technologies Inc. and a developer of regenerative therapies, announced the addition of an R&D laboratory to its facilities in Florida, USA.

Regulations

Europe

The translational pipeline from basic research to the delivery of innovative stem cell therapies is covered by a variety of European legal instruments, ranging from Marketing Authorization Regulations (Regulation (EC) No 1394/ 2007) to the directives on clinical trials (directive 2001/20/EC) and the guidelines for good clinical practice (directive 2001/83/EC, Directive 2009/120/EC).

Global Regenerative Therapies Market: Competitive Landscape

Key players operating in the global regenerative therapies market include, Shire Pharmaceuticals, Kinetic Concepts, Inc., Mesoblast Ltd., Nuo Therapeutics (Cytomedix Inc.), Advanced Cell Technology, Inc., BioStem Life Sciences, Akron Biotechnology, LLC, Organovo Holdings Inc., Orgenesis Inc., Pluristem Therapeutics Inc. , Genzyme, Athersys, Inc., RenovaCare, Inc. and Cytori Therapeutics, Inc.

March 2020: BioStem Life Sciences received its ISBT 128 registration from the International Council for Commonality in Blood Banking Automation

February 2019: Pluristem Therapeutics Inc. collaborated with NASA Ames Research Center to evaluate the potential of its PLX cell therapies in the prevention and treatment of medical conditions caused during space missions

Segmentation

  • By fabric type
    • allograft
    • Xenograft
    • Alloplast
  • By request
    • Soft tissue repair
    • Cardiovascular
    • Dental
    • Orthopedic
    • Treatment of CNS diseases
    • Others
  • Per end user
  • By region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa

Buy this report and get early access (fixed USD 2000 OFF) – https://www.coherentmarketinsights.com/promo/buynow/3712

About Us:

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Contact:

Consistent market information
1001 4th Ave, #3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Comments are closed.